Physician profile
Mark A Pavilack
NPI 1245238096
$3,478.24
in general payments reported to CMS, 2019-2025
27 companies · $917 in 2025
The $917 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $571 · 2021: $241 · 2022: $338 · 2023: $445 · 2024: $394 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.88 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $586.91 | 2019-2025 | Cequa |
| Allergan, INC. | $308.75 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $297.09 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $274.91 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $240.61 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $234.09 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Abbvie INC. | $230.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $162.07 | 2019-2023 | |
| Ocular Therapeutix, INC. | $156.23 | 2020 | |
| Mallinckrodt Hospital Products INC. | $144.35 | 2025 | Acthar |
| Harrow Eye, LLC | $130.83 | 2024-2025 | Vevye |
| Dompe US, INC. | $116.50 | 2022-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $87.66 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $66.91 | 2019 | |
| Oyster Point Pharma, INC. | $62.16 | 2022-2023 | Tyrvaya |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $46.82 | 2020 | |
| Oasis Medical, INC. | $39.10 | 2019 | |
| Rayner Intraocular Lenses Limited | $37.91 | 2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $37.48 | 2019-2022 | |
| Biotissue Holdings INC. | $36.30 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $35.70 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $32.12 | 2019-2022 | |
| Shire North American Group INC | $30.78 | 2019 | |
| Sight Sciences, INC. | $25.00 | 2019 | |
| Horizon Therapeutics Plc | $21.61 | 2022 | |
| Amgen INC. | $18.74 | 2025 | Tepezza |
| Tearlab Corp | $16.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pavilack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.